Browsing by Author "Jakubikova, Jana"
Now showing items 1-3 of 3
-
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma
Kikuchi, Shohei; Suzuki, Rikio; Ohguchi, Hiroto; Yoshida, Yashiro; Lu, Duo; Cottini, Francesca; Jakubikova, Jana; Bianchi, Giada; Harada, Takeshi; Gorgun, Guliu; Tai, Yu-Tzu; Richardson, Paul Gerard Guy; Hideshima, Teru; Anderson, Kenneth Carl (Springer Science and Business Media LLC, 2015-03-24)Histone deacetylase (HDAC) inhibitors have been extensively investigated as therapeutic agents in cancer. However, the biologic role of class IIa HDACs (HDAC4, 5, 7 and 9) in cancer cells, including multiple myeloma (MM), ... -
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells
Suzuki, Rikio; Kikuchi, Shohei; Harada, Takeshi; Mimura, Naoya; Minami, Jiro; Ohguchi, Hiroto; Yoshida, Yasuhiro; Sagawa, Morihiko; Gorgun, Gullu; Cirstea, Diana; Cottini, Francesca; Jakubikova, Jana; Tai, Yu-Tzu; Chauhan, Dharminder; Richardson, Paul G.; Munshi, Nikhil; Ando, Kiyoshi; Utsugi, Teruhiro; Hideshima, Teru; Anderson, Kenneth C. (Public Library of Science, 2015)Heat shock protein (HSP)90 inhibitors have shown significant anti-tumor activities in preclinical settings in both solid and hematological tumors. We previously reported that the novel, orally available HSP90α/β inhibitor ... -
Lenalidomide for the Treatment of Relapsed and Refractory Multiple Myeloma
Görgün, Güllü; Nijhof, Inger S; Raymakers, Reinier A; Lokhorst, Henk M; Groen, Richard W.j.; Jakubikova, Jana; Mitsiades, Constantine S; Hideshima, Teru; Laubach, Jacob; Richardson, Paul Gerard Guy; Anderson, Kenneth Carl; van de Donk, Niels WCJ (Dove Medical Press, 2012)Lenalidomide is an amino-substituted derivative of thalidomide with direct antiproliferative and cytotoxic effects on the myeloma tumor cell, as well as antiangiogenic activity and immunomodulatory effects. Together with ...